Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Acquired byAstraZeneca
Price$500M
Date8/2013

General Information

Websiteamplimmune.com
CategoryBioTech
Phone301-309-9800
Employees

Offices

Rockville, USA
9800 Medical Center Drive
Suite C-120
Rockville, MD, 20850
USA

People

President & Chief Executive Officer
Board Member
Sr VP and Chief Scientific Officer
Sr VP and Chief Operating Officer
Chairman

Funding

TOTAL $20M
FUNDING TOTAL $20M
Series A, 1/2006
Wellcome Trust
InterWest Partners
$20M

Tags

Amplimmune

Amplimmune is a product driven company that is developing immune-based biologics to treat patients in the areas of cancer, autoimmunity, transplantation and infectious diseases. Amplimmune’s scientific founders from Johns Hopkins University have identified several key immunological ligands and receptors. These immunological checkpoint and co-stimulatory molecules are the basis for developing a new class of biological treatments which modulate critical mechanisms in the body’s immune system with the aim of bettering the lives of patients suffering from aberrant immunological conditions.

Recent Milestones

Videos

Screenshots

Amplimmune screenshot
Above: Amplimmune
Uploaded: 4/22/10

Sources

  1. MedImmune agrees $500m cancer acquisition (businessweekly.co.uk) [edit]
  2. EDGAR [edit]
Edit This Page
Last Edited 4/9/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy